PT  - JOURNAL ARTICLE
AU  - Carter, Javan K.
AU  - Quach, Bryan C.
AU  - Willis, Caryn
AU  - Minto, Melyssa S.
AU - PGC-SUD Epigenetics Working Group
AU  - Hancock, Dana B.
AU  - Montalvo-Ortiz, Janitza
AU  - Corradin, Olivia
AU  - Logan, Ryan W.
AU  - Walss-Bass, Consuelo
AU  - Maher, Brion S.
AU  - Johnson, Eric Otto
TI  - Identifying novel gene dysregulation associated with opioid overdose death: A meta-analysis of differential gene expression in human prefrontal cortex
AID  - 10.1101/2024.01.12.24301153
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.12.24301153
4099  - http://medrxiv.org/content/early/2024/01/13/2024.01.12.24301153.short
4100  - http://medrxiv.org/content/early/2024/01/13/2024.01.12.24301153.full
AB  - Only recently have human postmortem brain studies of differential gene expression (DGE) associated with opioid overdose death (OOD) been published; sample sizes from these studies have been modest (N = 40-153). To increase statistical power to identify OOD-associated genes, we leveraged human prefrontal cortex RNAseq data from four independent OOD studies and conducted a transcriptome-wide DGE meta-analysis (N = 285). Using a unified gene expression data processing and analysis framework across studies, we meta-analyzed 20LJ098 genes and found 335 significant differentially expressed genes (DEGs) by OOD status (false discovery rate < 0.05). Of these, 66 DEGs were among the list of 303 genes reported as OOD-associated in prior prefrontal cortex molecular studies, including genes/gene families (e.g., OPRK1, NPAS4, DUSP, EGR). The remaining 269 DEGs were not previously reported (e.g., NR4A2, SYT1, HCRTR2, BDNF). There was little evidence of genetic drivers for the observed differences in gene expression between opioid addiction cases and controls. Enrichment analyses for the DEGs across molecular pathway and biological process databases highlight an interconnected set of genes and pathways from orexin and tyrosine kinase receptors through MEK/ERK/MAPK signaling to affect neuronal plasticity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is supported by the National Institute on Drug Abuse R01 DA043980 (PIs: Scacheri, Johnson, Ackbarian), R21 DA050160 (Pls: Montalvo-Ortiz, JL), R01 DA051390 (Pls: Logan, RW), R01 DA044859 (PI Walss-Bass), and P50 DA05471 (PIs: Eric Johnson)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Corradin O, Sallari R, Hoang AT, Kassim BS, Ben Hutta G, Cuoto L, et al. Convergence of case specific epigenetic alterations identify a confluence of genetic vulnerabilities tied to opioid overdose. Mol Psychiatry. 2022 Apr;27(4):215870. Mendez EF, Wei H, Hu R, Stertz L, Fries GR, Wu X, et al. Angiogenic Gene Networks are Dysregulated in Opioid Use Disorder: Evidence from MultiOmics and Imaging of Postmortem Human Brain. Mol Psychiatry. 2021 Dec;26(12):780312. Seney ML, Kim SM, Glausier JR, Hildebrand MA, Xue X, Zong W, et al. Transcriptional Alterations in Dorsolateral Prefrontal Cortex and Nucleus Accumbens Implicate Neuroinflammation and Synaptic Remodeling in Opioid Use Disorder. Biol Psychiatry. 2021 Oct 15;90(8):55062. Sosnowski DW, Jaffe AE, Tao R, Deep Soboslay A, Shu C, Sabunciyan S, et al. Differential expression of NPAS4 in the dorsolateral prefrontal cortex following opioid overdose. Drug Alcohol Depend Rep. 2022 Jun 1;3:100040.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are from previous published studies. All data produced in the present work are contained in the manuscript https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE174409 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE182321 https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002724.v1.p1 https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA739548